Indoco Remedies Limited (532612) Fair Value & Analysis
Healthcare · IN · Market cap ₹23.0B
Fair value as of: Jul 4, 2026
From 4 valuation models · updated today
Share price +16.8% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹164.85 – ₹339.46 · fair‑value band ₹58.43 – ₹135.14 · the ₹244.55 price screens above the ₹96.79 fair value. As of Jul 4, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Indoco Remedies Limited (532612) currently trades at ₹244.55, while our model-based Fair Value estimate is ₹96.79 — implying the stock looks roughly 60.4% overvalued today. We read business quality at 41/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Indoco Remedies Limited generated revenue of ₹11.7B at a net margin of 4.9%. Revenue grew 12.0% year over year. It earns a return on equity of 8.3%. The stock trades on a trailing P/E of 41.1. Fundamentals as of Jul 4, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 4, 2026. TTM = trailing twelve months.
About the company
Indoco Remedies Limited manufactures and sells formulations and active pharmaceutical ingredients in India and internationally. The company offers respiratory products, such as Karvol Plus, Febrex Plus, and Tuspel; stomatologicals products that include Sensodent-K, Sensoform, Sensodent-KF, Snowdent, Kidodent, Rexidin Plus, and Dentogel; gastro intestinal products, such as Carmicide, Cyclopam, Carmicide Drops, Cyclomeff, and Nosic; pain/analgesics products that include Lignox and T-lac; and opthalmological products, such as Renolen, Homide, Tobaren DM, and Mofloren-D. It also provides vitamins/minerals/nutrients that include Methycal, MCBM 69, SM Fibro, Durashape, Trucharge, and Apispur; Urology products, such as Cital, Cital UTI, and Cital-H; Cloben-G and Scabex for derma; ATM for anti-invectives; Otorex for otologicals; Obi X and KG-Low for anti-obesity; Hemsyl for blood related; Dexoren for Opthal/Otologicals; and Vepan, bactogard, and Oxipod for anti-infectives. In addition, the …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Indoco Remedies Limited reported revenue of ₹16.6B in FY2025 versus ₹12.4B in FY2021, a compound +7.6%/yr. Reported net income was −₹737M in FY2025.
Is 532612 fairly valued? → Check now
Similar stocks
6 more Drugs - Generic stocks, each showing price versus our Fair Value estimate (as of Jul 4, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Anuh Pharma Limited 506260 | ₹80.21 | ₹110.37 | +38% |
| Medicamen Biotech Limited 531146 | ₹262.00 | ₹98.91 | -62% |
| Coral Laboratories Limited 524506 | ₹605.55 | ₹779.49 | +29% |
| Gennex Laboratories Limited 531739 | ₹10.16 | ₹28.19 | +177% |
| Lactose (India) Limited 524202 | ₹103.75 | ₹130.91 | +26% |
| Beryl Drugs Limited 524606 | ₹21.22 | ₹17.12 | -19% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Indoco Remedies Limited (532612) undervalued?
What is the fair value of 532612?
What is the quality score of 532612?
What is the revenue of Indoco Remedies Limited (532612)?
What is the net profit margin of 532612?
Does Indoco Remedies Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.